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Abstract: 
Recognizing the similarities between Huntington’s disease (HD) pathophysiology and the neurotoxicology of 
various metals, we hypothesized that they may exhibit disease-toxicant interactions revealing cellular pathways 
underlying neurodegeneration. Here, we utilize metals and the STHdh mouse striatal cell line model of HD to 
perform a gene–environment interaction screen. We report that striatal cells expressing mutant Huntingtin 
exhibit elevated sensitivity to cadmium toxicity and resistance to manganese toxicity. This neuroprotective 
gene–environment interaction with manganese is highly specific, as it does not occur with iron, copper, zinc, 
cobalt, cadmium, lead, or nickel ions. Analysis of the Akt cell stress signaling pathway showed diminished 
activation with manganese exposure and elevated activation after cadmium exposure in the mutant cells. Direct 
examination of intracellular manganese levels found that mutant cells have a significant impairment in 
manganese accumulation. Furthermore, YAC128Q mice, a HD model, showed decreased total striatal 
manganese levels following manganese exposure relative to wild-type mice. Thus, this disease-toxicant 
interaction screen has revealed that expression of mutant Huntingtin results in heightened sensitivity to 
cadmium neurotoxicity and a selective impairment of manganese accumulation. 
Keywords: gene–environment Interactions,Huntington’s disease, manganese, neurodegeneration, 
neuroprotection, neurotoxicity. 
 
Article: 
In Huntington’s disease (HD), degeneration of the medium spiny neurons within the corpus striatum occurs well 
prior to other affected brain regions such as the cortex (Imarisio et al. 2008). This selective degeneration occurs 
despite widespread expression of the disease-causing, polyglutamine-expanded protein, huntingtin (HTT). Thus, 
other factors within the striatum may uniquely increase the vulnerability of this area to the pathophysiological 
mechanisms of HD. Interestingly, the toxicant 3-nitroproprionic acid (3NPA), a mitochondrial complex II 
inhibitor, exhibits an HD-like striatal specific neurodegeneration (Beal et al. 1993). One explanation of this 
common pathology is that both mutant HTT and 3NPA might impinge upon a shared pathophysiological 
vulnerability inherent to the striatum. Indeed, both HD and 3NPA toxicity cause mitochondrial dysfunction, 
oxidative stress, excitotoxicity, and altered iron and copper homeostasis (Dexter et al. 1991; Fox et al. 2007; 
Simmons et al. 2007). 
 
We postulate that toxicants acting upon pathophysiological targets modulated in HD will exhibit disease-
toxicant interactions, even if patients are not normally exposed to these toxicants. Furthermore, the 
identification of these interactions may uncover mechanisms of selective neurodegeneration because of 
environmental or genetic factors. Therefore, a disease-toxicant interaction screen may facilitate the 
identification of toxicants with common pathophysiological targets or mechanisms. The toxicological properties 
of metals are diverse, and include oxidative stress, deranged calcium signaling, activation of cell stress 
pathways, protein aggregation, and altered energy metabolism (Bush 2000; Zecca et al. 2004). Here, we exploit 
this broad toxicology to screen for gene–environment interactions between neurotoxic metals and the 
glutamine-expanded disease-causing HTT protein. We report the surprising discovery that expression of mutant 
HTT protects against manganese toxicity in part by substantially decreasing manganese accumulation during 
exposure. 
 
Materials and methods 
Chemicals, reagents, and cell culture supplies 
Cell culture media and supplements were obtained from Mediatech (Manassas, VA, USA) unless indicated. Cell 
lines were grown in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum (Atlanta Biologicals, 
Lawrenceville, GA, USA), L-glutamine, 400 µg/mL G418, and penicillin–streptomycin. Metals and toxicants 
used in survival assays were from Alfa Aesar (Ward Hill, MA, USA) unless indicated: 3NPA (Sigma, St Louis, 
MO, USA), Fe(III) chloride (VWR, West Chester, PA, USA), Mn(II) chloride, Cd(II) chloride, Co(II) chloride, 
Cu(II) chloride, Pb(II) chloride, Ni(II) sulfate, and Zn(II) chloride. Buffers and solutions for assays: 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) salt (VWR), Sorenson’s buffer (0.1 M glycine 
and 0.1 M NaCl2, pH 10.5), dimethyl sulfoxide (DMSO; Sigma). Phosphate-buffered saline (PBS) with 0.1% 
Triton X-100 (Sigma); 4% p-formaldehyde in PBS (diluted from 16% solution; Electron Microscopy Sciences, 
Hatfield, PA, USA) were used for cell imaging studies. 
 
Antibodies 
Antisera for western blotting include HTT (2166) 1 : 20 000 (Millipore, Billerica, MA, USA), Pan Akt 1 : 1000 
(Cell Signaling, Beverly, MA, USA), phospho-Akt 1 : 1000 (Cell Signaling), and actin 1 : 2000 (Developmental 
Studies Hybridoma Bank, Iowa City, IA, USA). Appropriate secondary antibodies from Jackson 
Immunoresearch Laboratories (West Grove, PA, USA) were used at 1 : 15 000 accordingly. 
 
Cell survival assays 
The clonal striatal cell lines – both mutant STHdh
Q111/Q111
 and wild-type STHdh
Q7/Q7
 – were a generous gift 
from Marcy Macdonald, PhD (Massachusetts General Hospital, Boston, MA, USA), and grown at 33°C 
(Cattaneo and Conti 1998; Trettel et al. 2000). STHdh
Q111/Q111
 and wild-type STHdh
Q7/Q7
 cells were plated at 
equal density the evening before treatment. Toxins or metals were added to the culture media the next morning 
and cells were exposed for 26–30 h. Cell viability was assessed by either trypan blue exclusion or MTT assay. 
Briefly, trypan blue exclusion – cells were harvested after exposure to various metals by trypsinization and 
exposed to trypan blue following published protocol (Ying et al. 2000). MTT assays were performed according 
to established protocols (Ehrich and Sharova 2000). Briefly, culture media was removed, and 500 µL of 0.5% 
MTT salt in minimal essential medium (Invitrogen, Carlsbad, CA, USA) containing fetal bovine serum and 
penicillin–streptomycin was added to each well for 4 h. Next, the minimal essential medium was removed and 
Sorenson’s buffer was diluted 2.5 mL into 20 mL of DMSO; 200 µL of Sorenson’s buffer in DMSO was added 
to the empty wells to dissolve the precipitate. The plates were returned to the incubator until all the MTT salt 
precipitate could no longer be visualized under a microscope; 60 µL from each well was removed and placed in 
a 96-well plate and absorbance was read at 570–590 nm. Cell survival data were normalized by genotype to the 
vehicle-only exposed control included in each independent sample set. 
 
Mutant HTT expression construct 
The polyglutamine expansion of 128 repeats was created by PCR of the CAG repeat from the YAC128Q mouse 
model and subcloned into a full-length HTT cDNA construct (gift from Juan Botas, Baylor College of 
Medicine, Houston, TX, USA). The new full-length mutant HTT cDNA was then subcloned into pCDNA3.1 
(Invitrogen), a mammalian expression vector to make full-length HTT with 128 glutamines in the 
polyglutamine domain (HTT[128Q]), mammalian expression construct (pHTT[128Q]). A control construct 
containing the full-length HTT cDNA in the reverse orientation, was used as a control vector in transfection 
experiments to control for the large size of pHTT[128Q] vector. The inverted control does not express the HTT 
protein, confirmed by western blot analysis (data not shown). 
 
 
 
Cell viability analysis in transfected cells 
Equal numbers of wild-type STHdh
Q7/Q7
 cells were plated onto glass coverslips ~10 h prior to transfection using 
lipofectAMINETM 2000 (Invitrogen). The pEGFP-N1 expression vector (Invitrogen) was co-transfected with 
pHTT[128Q] or the control vector at a 1 : 3 ratio to allow estimates of transfection efficiencies. Approximately 
70% of cells were green fluorescent protein (GFP) positive. Cells were treated with MnCl2 24 h post-
transfection and analyzed 30 h after exposure. Coverslips were harvested, washed in PBS with 0.1% Triton X-
100, fixed with 4% p-formaldehyde, washed again, and mounted onto slides with ProLong Gold antifade 
reagent with 4',6-diamidino-2-phenylindole (DAPI) nuclear stain (Invitrogen). 4',6-diamidino-2-phenylindole 
(DAPI)-positive cells were imaged by fluorescence microscopy using a Zeiss Axioplan microscope 
(Thornwood, NY, USA) with a 10x objective by systematic unbiased sampling of non-overlapping fields. 
Number of surviving cells per field was quantified using NIH ImageJ (Bethesda, MD, USA) by the threshold 
and analyze particles commands as previously described (Bowman et al. 2007). 
 
Westerns blot 
Equal numbers of wild-type and mutant STHdh cells were plated and treated with Mn(II) or Cd(II) for 3 or 30 
h. The cell pellets were lysed in lysis buffer [50 mM Tris, 150 mM NaCl2, 0.1% sodium dodecyl sulfate (SDS), 
1.0% Nonidet 40, 12 mM deoxcholic acid, 1x protease inhibitor cocktail (Sigma), and 1x phosphatase inhibitor 
cocktails I and II (Sigma)], and loaded by equal cell number or protein for sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. Western blots were visualized with Thermo Scientific Pierce Supersignal 
West Dura Extended Duration Chemiluminescent Substrate (Waltham, MA, USA) on an Ultralum Omega 12iC 
(Claremont, CA, USA). Measurements of integrated density of protein bands was performed using ImageJ 
(NIH), with background correction calculated using a signal ratio error model, as described (Kreutz et al. 2007). 
Calculations of relative signal were normalized to untreated wild-type or mutant sample for each set, as 
indicated. 
 
Animal manganese exposure 
All animal studies strictly followed protocols approved by the Vanderbilt University Institutional Animal Care 
and Use Committee and were adopted to minimize pain and distress of the animals. The FVB-
Tg(YAC128)53Hay/J mouse line (YAC128Q) was obtained from JAX (#004938, Bar Harbor, ME, USA) (Slow 
et al. 2003). The manganese-exposure protocol followed a previously published paradigm (Dodd et al. 2005). In 
brief, 3-month-old YAC128Q HD mutant mice and their wild-type littermates were injected subcutaneously 
with 50 mg/kg manganese chloride tetrahydrate. All injections were carried out blind to genotype. Injections 
were carried out on Days 0, 3, and 7. On Day 8, the animals were killed by cervical dislocation, the brain 
regions were dissected, tails clipped for genotyping, and trunk blood collected into heparin coated tubes. Tissue 
collection and graphite furnace atomic absorption spectroscopy (GFAAS) were performed blind to both 
genotype and exposure. The tissues were then flash-frozen for analysis of manganese content. Analysis of 
manganese content by GFAAS was performed blind to genotype and exposure. Genotyping was carried out 
according to a previously published method (#004938; from JAX) (Slow et al. 2003). 
 
Graphite furnace atomic absorption spectroscopy 
Manganese and iron concentrations were measured with GFAAS (AA240; Varian Inc., Palo Alto, CA, USA). 
STHdh cells were cultured and treated as described above for cell viability assays, harvested by trypsinization, 
washed multiple times in PBS and then flash-frozen until analysis. For analysis, cell pellets were thawed and 
digested in 200 µL ultrapure nitric acid for 24 h in a sandbath (60°C). Brain tissue samples were diluted 1 : 5 
(weight to volume) in 1x PBS and sonicated for 30 s. For protein analysis of the tissue samples, a 10 µL aliquot 
of the tissue homogenate was combined with 10 µL of lysis buffer. Homogenates were incubated on ice for 20 
min before being centrifuged at 10 000 g for 20 min at 4°C. The supernatant was then transferred to new tubes, 
and the total protein concentration was determined by bicinchoninic acid assay (Pierce, Rockford, IL, USA). An 
equal volume of ultrapure nitric acid was then added to the remaining homogenate and the sample was 
digested for 48 h in a sandbath (60
0
C). Manganese content was determined by the following protocol: A 20 µL 
aliquot of the digested sample was brought to 1 mL total volume with 2% nitric acid for analysis. Bovine liver 
(NBS Standard Reference Material; USDC, Washington, DC, USA) (10 µg Mn/g) was digested in ultrapure 
nitric acid and used as an internal standard for analysis (final concentration 10 µg Mn/L) as published 
previously (Anderson et al. 2009). 
 
Statistical analysis 
Univariate, multivariate, and repeated measures ANOVA were performed using SPSS software (SPSS, Inc., 
Chicago, IL, USA). Post hoc analysis and pair-wise comparisons were performed using Microsoft Excel 
(Redmond, WA, USA) by Student’s t-tests (two-tailed), except for comparison of normalized data versus 
control which were performed by testing for non-overlap of the 95% confidence interval, error bars are 
expressed as SEM. Animal manganese-exposure data were analyzed by multivariate ANOVA using blood 
manganese levels as a covariate. The alpha level for all of the analyses was set at p ≤ 0.05. 
 
Results 
Huntington’s disease-toxicant interaction screen 
To establish a gene–environment interaction model between metals and mutant htt, we utilized the HD mouse 
striatal cell line model developed by Marcy Macdonald. The model shares many phenotypic similarities with 
HD mouse models and human patients (Trettel et al. 2000; Imarisio et al. 2008). The striatal cell lines express 
full-length (wild-type or glutamine expanded) htt from the endogenous locus allowing comparisons of 
phenotypes between wild-type (STHdh
Q7/Q7
) and mutant (STHdh
Q111/Q111
) cells. The initial screen focused on 
cell survival as a basic toxicological phenotype. Previous research by Macdonald and colleagues has shown that 
the mutant cell line (STHdh
Q111/Q111
) line has increased sensitivity to the toxicant 3NPA (Ruan et al. 2004). 
Therefore, as a positive control, we examined cell survival in the striatal cell model following 30 h exposure to 
3NPA. We confirmed that the mutant STHdh
Q111/Q111
 line has a significant (p < 0.05) decrease in cell survival 
relative to wild-type cells after 3NPA exposure (Fig. S1). 
 
After validating the HD striatal model for detection of gene–environment interactions relevant to HD, we 
initiated a cell survival screen to determine whether expression of mutant htt modulates sensitivity to a diverse 
set of metal toxicants. We screened eight neurotoxic metal ions, Fe(III), Cu(II), Pb(II), Co(II), Zn(II), Ni(II), 
Cd(II), and Mn(II), by generating concentration–response curves (Fig. 1). Metal concentrations were chosen to 
generate a survival curve spanning non-toxic to highly toxic exposures. We were unable to induce a high degree 
of cell death (> 40%) for Fe(III) and Pb(II) because of the insufficient solubility of these metals at higher 
concentrations. Nevertheless, statistical analysis of cell survival by two-way ANOVA revealed a significant 
effect of exposure on cell survival for each of the eight metals (p < 0.001). Wild-type and mutant STHdh cell 
line survival curves were indistinguishable for Fe(III), Cu(II), Pb(II), Co(II), Zn(II), and Ni(II) (Fig. 1). In 
contrast, Cd(II) and Mn(II) both showed differential effects on wild-type and mutant cell survival (Fig. 1). The 
mutant STHdh
Q111/Q111
 cells displayed an increased sensitivity to Cd cytotoxicity. Statistical analysis by two-
way univariate ANOVA found a significant effect of genotype [F(1,29) = 5.3 1, p = 0.029] on cell survival. Post 
hoc analysis indicated that the wild-type line had significantly (p < 0.05) higher survival at 50 µM Cd(II) 
relative to mutant cells (Fig. 1). Analyses of Mn(II) toxicity in the STHdh cells revealed an unexpected gene– 
environment interaction, in which cells expressing mutant htt were resistant to Mn(II) toxicity. Statistical 
analysis by two-way repeated measures ANOVA found a significant effect of genotype [F(1,8) = 323.2, p < 
0.001] on cell survival. 
 
Post hoc analysis indicated that the mutant line had significantly (p < 0.01) higher survival at 50, 100, and 300 
µM Mn(II) relative to wild-type cells (Fig. 1). 
 
 
 
 
 
Mn(II) survival curve 
The MTT assay used in the initial screen is an indirect measure of cell survival. To determine if the HD-
manganese interaction observed by MTT assay was directly because of changes in cell survival we used the 
trypan blue exclusion assay (Fig. 2). This independent and expanded survival curve for Mn(II) confirmed that 
the gene–environment interaction seen by MTT assay was due to changes in cell survival rather than just 
differences in mitochondrial reductase activity (Figs 1 and 2). Statistical analysis by two-way univariate 
ANOVA found a significant effect of genotype [F(1,88) = 59.3, p < 0.00 1 ] on cell survival with Mn(II) 
exposure, in addition a two-way interaction between genotype and Mn(II) exposure was detected [F(10,88) = 2.1, 
p = 0.039] indicating that each genotype had a unique Mn-response curve. Over a broad range of Mn(II) 
exposures (40–300 µM) the HD mutation limited Mn(II) cytotoxicity of the metal when compared with the 
wild-type cell line (p < 0.05). At the highest concentrations of Mn(II) tested (400–500 µM), the toxicity is not 
significantly different between wild-type and mutant cell lines. Therefore, the survival curve for Mn(II) shows a 
gene– environment interaction wherein mutant htt counters the toxic effects of Mn(II) exposure. 
 
40 µM Mn(II) exposure does not significantly alter htt protein levels 
The htt gene has been shown to be Fe-responsive (Hilditch-Maguire et al. 2000) and Mn(II) exposure is known 
to alter cellular Fe levels (Zheng et al. 1999). To test the hypothesis that manganese exposure might influence 
cell viability by altering htt protein levels, we used western blot analysis to measure mutant and wild-type htt 
levels in the HD cell model (Fig. 3a). Quantitative analysis demonstrated that htt levels were not significantly 
altered in wild-type or mutant striatal cells after exposure to 40 µM Mn(II) for 30 h (Fig 3b). As previously 
reported, mutant htt levels are decreased in the STHdh
Q111/Q111
 cells relative to wild-type protein levels in the 
wild-type cell line (Fig. 3) (Trettel et al. 2000). 
 
 
Expression of mutant HTT is sufficient for the manganese-resistance phenotype 
The wild-type and mutant striatal cell lines are independent lines. Thus, differences in their response to Mn(II) 
exposure might be because of expression of mutant htt or other inherent differences between the two lines. To 
determine if the Mn(II) resistance phenotype is due to expression of mutant htt we transiently transfected full-
length human mutant HTT with 128 repeats (HTT[128Q]) or a control vector into the wild-type STHdh
Q7/Q7
 
cells. Transfected cells were exposed to vehicle, 40 µM Mn(II), or 100 µM Mn(II) and cell survival assessed by 
microscopy (Fig. 4). Statistical analysis by two-way univariate ANOVA revealed a significant difference 
between HTT[128Q] and control transfected cells [F(1,108) = 7.33, p = 0.008] and a significant two-way 
interaction between Mn(II) exposure and transfection [F(2,108) = 3.92, p = 0.023]. Post hoc analysis indicated 
significantly higher cell survival following Mn(II) exposure in the HTT[128Q] transfected cells relative to 
control cells (Fig. 4). Therefore, expression of mutant HTT is sufficient to confer resistance to manganese 
toxicity. 
 
Diminished Mn(II)-dependent Akt activation in HD striatal cells 
As changes in S473-phosphorylated Akt (S473-P-Akt) levels are associated with both Mn(II) toxicity and HD, 
we hypothesized that this signaling pathway would show disease-toxicant interactions (Humbert et al. 2002; 
Gines et al. 2003a; Colin et al. 2005; Warby et al. 2005; Bae et al. 2006; Liao et al. 2007; Lee et al. 2009). To 
begin we quantified S473-P-Akt levels following a 30-h exposure to 40 µM Mn(II). This exposure led to a 
manganese-dependent increase in S473-P-Akt levels (p < 0.05) in wild-type cells, yet mutant cells showed no 
detectable change in S473-PAkt levels relative to untreated mutant cells (data not shown). As expected from 
previous work, S473-P-Akt levels were elevated in the mutant line versus wild-type (Gines et al. 2003a). Thus, 
the lack of a manganese-dependent increase in S473-P-Akt in the mutant cells might be because of a general 
inability of these cells to increase S473-P-Akt levels beyond their already higher basal levels. To determine if 
higher levels of Mn(II) are capable of increasing S473-P-Akt levels, we exposed cells for a shorter time point (3 
h) to allow us to collect protein before significant cell death. At this time point, other studies reported strong 
manganese-dependent increases in S473-PAkt levels (Bae et al. 2006; Lee et al. 2009). We found that mutant 
STHdh
Q111/Q111
 cells were capable of increasing S473-P-Akt levels in response to high concentrations of Mn(II). 
However, while 40 µM Mn(II) was sufficient to significantly raise S473-P-Akt above basal levels in wild-type 
cells (p < 0.05), we did not detect a significant increase in S473-P-Akt above its higher basal levels in mutant 
cells until 200 µM Mn(II) or higher (p < 0.05) (Figs 5 and S2). Interestingly, at exposures of 100 µM and 
above, the levels of S473-P-Akt in the wild-type cells increased sufficiently to equal the levels seen in mutant 
cells exposed at the same Mn(II) concentration (Fig. S2). Controlling for the elevated S473-P-Akt levels in the 
mutant cells by normalizing the basal levels of each genotype to 100%, mutant cells exhibited a significant 
decrease in S473-P-Akt activation relative to wild-type cells across all tested Mn(II) concentrations (p < 0.05) 
(Fig. 5). 
 
Enhanced Cd(II)-dependent Akt activation in HD striatal cells 
To evaluate whether the differential phosphorylation of Akt following Mn(II) exposure in mutant cells is a 
specific marker of the manganese-HD interaction, we tested the effect of Cd(II) exposure on S473-P-Akt levels 
in the STHdh cell lines. We chose to test cadmium given its opposite effect from manganese on cell survival 
(Fig 1). Published evidence has demonstrated that Cd(II) exposure leads to phosphorylation of Akt at S473 in a 
variety of cell types (Thevenod 2009). A 3-h exposure of STHdh cells to 50 µM Cd(II) increased S473-P-Akt 
levels in both wild-type and mutant lines (Figs 5 and S2). Indeed, despite the elevated basal levels of S473-P-
Akt, Cd(II) exposed mutant STHdh
Q111/Q111
 cells had significantly higher levels of S473- P-Akt than wild-type 
cells (p < 0.05) (Fig. S2). Controlling for the difference in basal S473-P-Akt levels, mutant and wild-type cells 
both had a similar approximately twofold increase in S473-P-Akt levels (Fig. 5). Thus, the elevated basal S473-
P-Akt levels in the mutant cells do not limit per se the capacity of mutant cells to increase the S473-P-Akt to 
total Akt ratio. 
 
Cellular manganese accumulation is substantially impaired by mutant htt 
Given the severely blunted S473-P-Akt response of the mutant cells to Mn(II) exposure, we tested the 
hypothesis that the expression of mutant htt impedes the cellular stress response to Mn(II) by decreasing 
accumulation of manganese during exposure. We measured total intracellular manganese and iron levels 
following Mn(II) exposure in the STHdh
Q7/Q7
 and STHdh
Q111/Q111
 cell lines by GFAAS (Garcia et al. 2007). We 
observed that the STHdh
Q111/Q111
 cells accumulated fourfold (p < 0.005) and 10-fold (p < 0.001) less manganese 
after a 30-h exposure to 40 µM Mn(II) and 100 µM Mn(II), respectively (Fig. 6a). 
 
No difference in basal manganese levels was seen, however, the manganese levels in the vehicle-only samples 
were near the lower detection limit of the GFAAS. Examination of total iron levels in these cells revealed no 
differences between wild-type and mutant cells at basal state or 40 µM Mn(II) exposure, though wild-type cells 
showed a trend toward elevated total iron at the 100 µM Mn(II) exposures (p = 0.13) not seen in the mutant 
cells (Fig. 6b). Thus, differences in manganese accumulation between wild-type and mutant cells did not 
correlate with significant changes in iron accumulation. 
 
Striatal specific deficit in total manganese accumulation in YAC128Q HD mouse model 
To determine if expression of mutant HTT influences manganese accumulation in vivo, we exposed 3-month 
(presymptomatic) YAC128Q HD mice and wild-type litter-mates to Mn(II) using a subcutaneous manganese-
exposure paradigm (Slow et al. 2003; Dodd et al. 2005). Loss of striatal volume in the YAC128Q HD mouse 
model is absent as late as 6 months of age, and is first detected at 9 months of age (Slow et al. 2003). Analyses 
of cerebellar, cortical, hippocampal, and striatal manganese levels by GFAAS indicated that Mn(II) exposed 
wild-type animals had increased total manganese levels in all four brain regions with the striatum having the 
greatest accumulation (Fig. 7). Cerebellum, cortex and hippocampus showed similar increases in manganese 
levels between wild-type and mutant animals, while striatum from wild-type Mn(II) exposed animals showed 
higher levels than mutant (1.51 vs. 0.92 nmol Mn/mg protein). A multivariate two-way ANOVA was used to 
analyze regional manganese levels (Table S1). ANOVA found a significant effect of Mn(II) exposure for each 
of the four brain regions (p < 0.05). A significant effect of genotype and a genotype by exposure two-way 
interaction was found for striatum only (p < 0.05). Post hoc analysis of striatal manganese levels showed 
significantly less (p < 0.05) manganese accumulation in mutant versus wild-type Mn(II) exposed animals (Fig. 
7). We also examined iron levels in the same brain tissues. Data were analyzed by multivariate two-way 
ANOVA model (Fig. S3 and Table S2). This analysis failed to find a significant effect of Mn(II) exposure or a 
two-way genotype by Mn(II) exposure interaction for iron levels in any brain region, though a significant 
genotype difference in cerebellar iron levels was seen (p = 0.024). Finally, we have confirmed the impaired 
striatal manganese accumulation in the YAC128Q HD animals in an independent set of animals by inductively 
coupled plasma mass spectrometry (data not shown). Therefore, a mouse model of HD that recapitulates the 
selective degeneration of the corpus striatum observed in patients, also exhibited an early and selective deficit in 
striatal manganese accumulation after Mn(II) exposure. 
 
 
Discussion 
Our study has used a disease-toxicant interaction screen to evaluate toxicants that may share pathophysiological 
mechanisms underlying HD neurodegenerative processes. The approach exploited the diverse toxicology of 
metals to reveal processes that may underlie gene–environment interactions in disease. Metals were the toxicant 
of choice for this screen because they are known to alter cellular pathways also implicated in HD pathology. We 
tested eight metals and the mitochondrial complex II inhibitor 3NPA for modification of cell survival in the 
presence of either wild-type htt or a polyglutamine-expanded form of the protein. 3NPA was a positive control 
showing increased toxicity in the presence of the glutamine-expansion as previously reported (Fig. S1). The 
wild-type and HD mutant cell lines showed no difference in their response to the metals Cu(II), Fe(III), Pb(II), 
Co(II), Ni(II), or Zn(II) (Fig. 1). In contrast, the mutant HD cell line was found to have enhanced sensitivity to 
Cd(II) toxicity, and resistance to Mn(II) toxicity. The selective effect of these two metals strongly suggests that 
the HD mutation can alter the influence of specific environmental toxicants on striatal neurons and validates the 
utility of a disease-toxicant interaction screen to identify pathways of gene–environment interactions. 
 
Oxidative stress is known to be a key factor in copper and iron mediated toxicity and is a potential mechanism 
of HD pathology. The lack of a significant difference in toxicity between genotypes with these metals is 
consistent with an earlier study that found no difference in vulnerability to oxidative stress in another HD cell 
model (Fig. 1) (Snider et al. 2003). Furthermore, it suggests that a change in sensitivity to oxidative stress is not 
the source of the altered vulnerability of mutant STHdh
Q111/Q111
 cells to cadmium, manganese or 3NPA (Figs 1 
and S1). 
 
Cadmium and 3NPA exert their toxic effects directly on the mitochondria (Li et al. 2003; Mao et al. 2006). The 
mutant STHdh
Q111/Q111
 cells are reported to have an increased susceptibility to multiple mitochondrial stressors 
(Gines et al. 2003b; Seong et al. 2005; Oliveira et al. 2006). More recently, Cd(II) toxicity has been linked to 
aberrant activation of mitogen-activated protein kinases and the mammalian target of rapamycin cell signaling 
pathways (Lopez et al. 2006; Chen et al. 2008). Disruption of these signaling pathways has also been suggested 
in HD (Ravikumar et al. 2004; Apostol et al. 2006). Further investigation is needed to determine the relative 
contribution of these and other mechanisms to the increased sensitivity of STHdh
Q111/Q111
 cells to Cd(II) 
toxicity. 
 
Activation of Akt via S473 phosphorylation has been associated with neuroprotection (Brunet et al. 2001). Yet, 
we found that the increased sensitivity of mutant STHdh
Q111/Q111
 cells to Cd(II) toxicity correlated with 
increased S473-P-Akt levels relative to wild-type exposed cells, while the decreased sensitivity to Mn(II) 
toxicity correlated with a blunted S473-PAkt response. While this observation does not rule out a 
neuroprotective role for Akt signaling in Mn(II) or Cd(II) toxicity, it does demonstrate that enhanced Akt 
activation between wild-type and HD mutant cells does not correlate with improved cell survival following 
exposure to these environmental toxicants in the STHdh cellular model. Future studies are needed to explore 
changes in Akt signaling following exposure to these metals in animal models of HD. Besides Akt, several 
other kinases are reported to be activated upon Mn(II) exposure including extracellular signal-regulated kinase, 
p38, and c-Jun N-terminal kinase (Bae et al. 2006; Moreno et al. 2008; Lee et al. 2009). Additionally, Cd(II) has 
been shown to affect mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in 
hippocampal slices (Rigon et al. 2008). It will be interesting to evaluate how HD influences activation of these 
and other signaling systems that are modulated by Mn(II) and Cd(II). 
 
 
 
We report the discovery that expression of the disease-causing allele of htt suppresses Mn(II) toxicity (Figs 1, 2, 
and 4). This neuroprotective interaction was highly metal specific, suggesting a unique relationship between 
mutant htt and Mn(II) toxicity. We found no evidence that htt protein levels are altered by 40 µM Mn(II) 
exposure, indicating that survival differences between cells does not depend on changes in the expression of the 
toxic mutant htt protein. However, it remains possible that higher levels of Mn(II) exposure may be able to alter 
the expression of htt. Importantly, dosimetry studies have revealed that manganese concentrations in rodent 
striatum are normally between 4 and 18 µM, and can increase to as high as 70 µM in Mn(II) exposed animals 
(Aschner et al. 2005). Thus, our observation of a htt-manganese gene–environment interaction at Mn(II) 
exposures in this range are potentially pathologically relevant. Further work is needed to evaluate the 
relationship between manganese homeostasis and HD. 
 
The significant decrease in net manganese accumulation in the mutant cells justifies the strong Mn(II) resistance 
phenotype, and suggests a manganese homeostatic defect because of mutant HTT. Of particular note, a 
comparison of cell survival and total manganese accumulation reveals that wild-type cells exposed to 40 µM 
Mn(II) have statistically indistinguishable cell survival and total manganese levels relative to mutant cells 
exposed at 100 µM Mn(II) (Figs 2 vs. 6a). These data strongly suggest that impairment in manganese 
accumulation may contribute, at least in part, to the Mn(II) resistance phenotype of STHdh
Q111/Q111
 cells.      
Furthermore, the cellular disease-toxicant interaction accurately predicted a defect in manganese accumulation 
in the striatum of the YAC128Q HD mouse model. Indeed, the in vivo study showed a manganese-
accumulation deficit in the very brain region most vulnerable in HD (Fig. 7). However, additional work is 
needed to determine if the specific nature of the manganese-accumulation defect is similar between the cellular 
and animal models (e.g. extracellular vs. intracellular accumulation). We propose three possible general mecha-
nisms for the deficient manganese accumulation in the mutant STHdh
Q111/Q111
 cells: (i) a decrease in manganese 
uptake, (ii) an increase in manganese export, and (iii) a decrease in manganese storage capacity. Future studies 
will explore the kinetics of the manganese transport defect to elucidate the cellular mechanism and transporters 
involved. 
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Additional Supporting information may be found in the online version of this article: 
 
Fig. S1 Survival curve for 3NPA cytotoxicity in wild-type versus HD striatal cell lines. 
Fig. S2 Diminished manganese-dependent Akt phosphorylation in HD striatal cells normalized wild-type 
vehicle control. 
Fig. S3 Iron levels in Mn(II)-exposed animals. 
Table S1 Analysis of regional manganese levels by multivariate two-way ANOVA 
Table S2 Analysis of regional iron levels by multivariate two-way ANOVA 
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